JP2020518243A5 - - Google Patents

Download PDF

Info

Publication number
JP2020518243A5
JP2020518243A5 JP2019559720A JP2019559720A JP2020518243A5 JP 2020518243 A5 JP2020518243 A5 JP 2020518243A5 JP 2019559720 A JP2019559720 A JP 2019559720A JP 2019559720 A JP2019559720 A JP 2019559720A JP 2020518243 A5 JP2020518243 A5 JP 2020518243A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequences
light chain
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019559720A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020518243A (ja
JP7257967B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/030350 external-priority patent/WO2018204303A1/en
Publication of JP2020518243A publication Critical patent/JP2020518243A/ja
Publication of JP2020518243A5 publication Critical patent/JP2020518243A5/ja
Application granted granted Critical
Publication of JP7257967B2 publication Critical patent/JP7257967B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019559720A 2017-05-01 2018-05-01 抗pd1抗体試薬に関する方法および組成物 Active JP7257967B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762492533P 2017-05-01 2017-05-01
US62/492,533 2017-05-01
PCT/US2018/030350 WO2018204303A1 (en) 2017-05-01 2018-05-01 Methods and compositions relating to anti-pd1 antibody reagents

Publications (3)

Publication Number Publication Date
JP2020518243A JP2020518243A (ja) 2020-06-25
JP2020518243A5 true JP2020518243A5 (enExample) 2021-05-13
JP7257967B2 JP7257967B2 (ja) 2023-04-14

Family

ID=64016985

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019559720A Active JP7257967B2 (ja) 2017-05-01 2018-05-01 抗pd1抗体試薬に関する方法および組成物

Country Status (6)

Country Link
US (3) US11427636B2 (enExample)
EP (1) EP3619230A4 (enExample)
JP (1) JP7257967B2 (enExample)
CN (1) CN110809582B (enExample)
CA (1) CA3060935A1 (enExample)
WO (1) WO2018204303A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018204303A1 (en) 2017-05-01 2018-11-08 The Children's Medical Center Coporation Methods and compositions relating to anti-pd1 antibody reagents
PL3946377T3 (pl) 2019-04-03 2026-04-20 Orega Biotech Terapie skojarzone oparte na inhibitorach pd1 i il-17b
US20230045494A1 (en) 2020-02-28 2023-02-09 Orega Biotech Combination therapies based on ctla4 and il-17b inhibitors
EP4178984A4 (en) * 2020-07-13 2024-11-20 The Children's Medical Center Corporation NOVEL ANTI-PD1 ANTIBODIES TO INHIBIT T-CELL ACTIVITY
WO2022250070A1 (ja) * 2021-05-28 2022-12-01 日本化薬株式会社 ウベニメクスと免疫チェックポイント阻害剤の併用
EP4257609A1 (en) 2022-04-08 2023-10-11 iOmx Therapeutics AG Combination therapies based on pd-1 inhibitors and sik3 inhibitors

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622871A (en) 1987-04-27 1997-04-22 Unilever Patent Holdings B.V. Capillary immunoassay and device therefor comprising mobilizable particulate labelled reagents
US4135884A (en) 1977-08-29 1979-01-23 Shen James T Gamma stick
US4305924A (en) 1979-08-08 1981-12-15 Ventrex Laboratories, Inc. Method and apparatus for performing in vitro clinical diagnostic tests using a solid phase assay system
US4444880A (en) 1982-07-27 1984-04-24 Syva Company Periodate removal of ascorbate interference in dipsticks for immunoassays
ES2150428T3 (es) 1987-04-27 2000-12-01 Unilever Nv Ensayos de union especifica.
US4943522A (en) 1987-06-01 1990-07-24 Quidel Lateral flow, non-bibulous membrane assay protocols
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0566695B1 (en) 1991-01-11 1999-06-02 Quidel Corporation A one-step lateral flow assay and nonbibulous support used therein
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US6824989B1 (en) 2000-09-01 2004-11-30 Upstate Biotechnology, Inc. Recombinant monoclonal antibody to phosphotyrosine-containing proteins
US6565808B2 (en) 2001-05-18 2003-05-20 Acon Laboratories Line test device and methods of use
US6902932B2 (en) 2001-11-16 2005-06-07 Tissue Regeneration, Inc. Helically organized silk fibroin fiber bundles for matrices in tissue engineering
US20110009960A1 (en) 2001-11-16 2011-01-13 Allergan, Inc. Prosthetic fabric structure
JP4694128B2 (ja) 2002-01-30 2011-06-08 ザ ブライハム アンド ウイメンズ ホスピタル, インコーポレイテッド TIM−3、Th1特異的細胞表面分子に関連した組成物および方法
EP1685159B1 (en) 2003-10-03 2012-08-01 Brigham & Women's Hospital Tim-3 polypeptides
ATE541928T1 (de) 2005-03-31 2012-02-15 Calando Pharmaceuticals Inc Inhibitoren der untereinheit 2 der ribonukleotidreduktase und ihre verwendungen
PL2161336T5 (pl) * 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
CA2682701A1 (en) 2007-03-20 2008-09-25 Serica Technologies, Inc. Prosthetic device and method of manufacturing the same
WO2010001617A1 (en) 2008-07-04 2010-01-07 Ono Pharmaceutical Co., Ltd. Use of an efficacy marker for optimizing therapeutic efficacy of an anti-human pd-1 antibody on cancers
US9701749B2 (en) 2011-08-11 2017-07-11 Ono Pharmaceutical Co., Ltd. Therapeutic agent for autoimmune diseases comprising PD-1 agonist
AU2013263076B2 (en) * 2012-05-15 2017-08-31 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
LT2904011T (lt) * 2012-10-02 2017-11-10 Bristol-Myers Squibb Company Anti-kir antikūnų ir anti-pd-1 antikūnų derinys, akirtas vėžio gydymui
LT3702373T (lt) 2013-09-13 2022-11-10 Beigene Switzerland Gmbh Anti-pd1 antikūnai ir jų naudojimas terapijai ir diagnostikai
WO2015112790A2 (en) * 2014-01-24 2015-07-30 Children's Medical Center Corporation High-throughput mouse model for optimizing antibody affinities
EP3151973B1 (en) 2014-06-09 2018-08-15 The Procter and Gamble Company Flushing dispensers for delivering a consistent consumer experience
CN105061597B (zh) * 2015-06-09 2016-04-27 北京东方百泰生物科技有限公司 一种抗pd-1的单克隆抗体及其获得方法
WO2016210129A1 (en) 2015-06-23 2016-12-29 Memorial Sloan-Kettering Cancer Center Novel pd-1 immune modulating agents
CA2991976A1 (en) 2015-07-13 2017-01-19 Cytomx Therapeutics, Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
EP3355920A4 (en) 2015-09-29 2019-05-15 Celgene Corporation PD-1 BINDING PROTEINS AND METHOD OF USE THEREOF
WO2018204303A1 (en) 2017-05-01 2018-11-08 The Children's Medical Center Coporation Methods and compositions relating to anti-pd1 antibody reagents

Similar Documents

Publication Publication Date Title
JP2025160458A5 (enExample)
JP2024522360A5 (enExample)
JP2023504572A5 (enExample)
JP2022512132A5 (enExample)
JP2022521551A5 (enExample)
JP2019116474A5 (enExample)
JP2015172045A5 (enExample)
JP2019527553A5 (enExample)
JP2021516051A5 (enExample)
JP2020533016A5 (enExample)
JP2019535670A5 (enExample)
JP2019532619A5 (enExample)
RU2017145150A (ru) Антитело против pdl-1, его фармацевтическая композиция и применение
JP2008538289A5 (enExample)
JP2023540526A5 (enExample)
JP2020534830A5 (enExample)
JP2018516853A5 (enExample)
JP2010513539A5 (enExample)
JP2021517152A5 (enExample)
RU2019143101A (ru) Новое анти-с-мет антитело и его применение
JP2018522888A5 (enExample)
JP2021530244A5 (enExample)
JP2012519492A5 (enExample)
JP2024001073A5 (enExample)
JP2020518248A5 (enExample)